AbobotulinumtoxinA: Phase IIa data

A double-blind, international Phase IIa trial in 47 patients with neurogenic detrusor overactivity secondary to multiple sclerosis (MS) or spinal cord injury (SCI) not adequately managed by anticholinergics showed that a single 750 unit dose of Dysport in either 15 or 30 sites in the detrusor muscle led to a significant mean reduction of >75% in urinary incontinence episodes from baseline to week 12, the primary endpoint, vs. placebo. Ipsen said that efficacy was confirmed by improvement in urodynamic parameters and quality of life, but could not be reached for details or next steps for Dysport in the indication. ...